

SCIENTIFIC REPORTS

OPEN

Dioscorea bulbifera polysaccharide and cyclophosphamide combination enhances anti-cervical cancer effect and attenuates immunosuppression and oxidative stress in mice

Hongxia Cui^{1,2}, Ting Li¹, Liping Wang³, Yan Su¹ & Cory J. Xian³

Received: 18 June 2015

Accepted: 07 December 2015

Published: 12 January 2016

Cyclophosphamide (CTX) is commonly used in cancer chemotherapy, which causes immunosuppression and tissue oxidative stress at high doses. As potential protective agents, some polysaccharides were shown to have anti-tumor, anti-inflammatory and/or anti-oxidant properties. This study explored potential effects of oral treatment of *Dioscorea bulbifera* polysaccharides (DBLP at 100 or 150 mg/kg) in U14 cervical tumor-bearing mice treated with CTX (25 mg/kg). While CTX suppressed tumor growth (65.4% inhibition) and DBLP alone also inhibited tumor (25.6% at 100 mg/kg or 37.6% at 150 mg/kg), CTX+DBLP combination produced tumor inhibition rates of 5.6 (for 100 mg/kg DBLP) or 9% (for 150 mg/kg) higher than CTX alone. While tumor itself and CTX treatment reduced thymus and/or spleen/body weight indices, DBLP alone or CTX + DBLP combination attenuated this reduction. DBLP lowered peripheral blood T-cell subpopulation CD⁴⁺/CD⁸⁺ ratio, and DBLP+CTX combination attenuated CTX effect in lifting CD⁴⁺/CD⁸⁺ ratio. Tumor itself and CTX treatment heightened oxidative stress (with decreased superoxide dismutase but increased lactate dehydrogenase and malondialdehyde levels in serum and tissues), which was attenuated by DBLP treatment, and DBLP+CTX combination suppressed CTX-induced oxidative stress. Combination use of DBLP with CTX can potentially enhance CTX anti-tumor effect and can attenuate CTX-induced immunosuppression and oxidative stress in U14 cervical tumor-bearing mice.

Cervical cancer is a common female cancer, which has over 500,000 new cases diagnosed every year globally¹. Despite the availability of low-cost and effective methods to prevent cervical cancer, it still kills thousands of women worldwide each year, most of whom are in low-income countries². Although there has been continuing research for more effective and better treatments, surgery, radiotherapy, and chemotherapy are the most commonly used modalities in cervical cancer treatment. While fertility-sparing surgical treatment is only applicable to the young patients and the patients in the early cancer stage³, radiotherapy and chemotherapy unfortunately often cause many side effects, such as organ toxicity and immunotoxicity⁴.

Cyclophosphamide (CTX) is a commonly used chemotherapeutic drug. As a DNA alkylating agent, its active metabolite can kill cancer cells^{5–7} and can also have a negative immunomodulatory effect. The effect of CTX on T cells is known to be complex and dose-dependant, and T cell lymphopenia and immunosuppression can develop at its higher doses^{8,9}. In addition, CTX generates free radicals and therefore causes oxidative stress in tissues and cells¹⁰. Therefore, supplementary treatments that could enhance CTX antitumor effect and attenuate its adverse effects would be of significant importance and will lessen the side effects of high-dose CTX treatment¹¹.

¹College of Environmental and Chemical Engineering, Yanshan University, Qinhuangdao, Hebei 066004, China.

²Hebei Province Key Laboratory of Applied Chemistry, Qinhuangdao, Hebei 066004, China. ³Sansom Institute for Health Research and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia. Correspondence and requests for materials should be addressed to H.C. (email: hxcui@ysu.edu.cn) or C.J.X. (email: cory.xian@unisa.edu.au)

Group	Initial weight (g)	Final weight (g)	Body weight increased (%)
Blank control	18.1 ± 0.5	25.0 ± 0.9	38.1 ± 0.8**
Positive control	18.3 ± 0.6	22.8 ± 0.9	24.6 ± 0.5**
Negative control	18.1 ± 0.3	21.3 ± 0.7	17.7 ± 1.3**
Low dose group	17.9 ± 0.7	23.2 ± 0.5	29.6 ± 0.3**
High dose group	17.7 ± 0.6	23.4 ± 0.4	32.2 ± 0.3**
Low dose group + CTX	18.0 ± 0.5	24.2 ± 0.8	34.4 ± 0.6**
High dose group + CTX	18.1 ± 0.8	24.5 ± 1.1	35.4 ± 0.4**

Table 1. The weights of the animals of the experimental groups. Compared with the negative control group, ** $P < 0.01$. CTX – cyclophosphamide.

To enhance the anti-cancer efficacy and reduce the toxicity of CTX, recently, there have been various studies investigating potential adjuvant treatments that can prevent/attenuate the adverse effects. Polysaccharides are the major bioactive substances in medicinal herbs¹². Many studies have reported that combining polysaccharides with chemotherapy might enhance the anti-tumor response, reduce the toxicity of chemotherapy, and improve quality of life^{13,14}. Some polysaccharides are known to possess various biological activities, including immunomodulation, anti-viral, anti-tumor, anti-oxidation, and anti-inflammation¹⁵. Among these biological activities, the immunomodulatory effect of some polysaccharides is most remarkable¹⁶. Many studies have reported that some polysaccharides are ideal immune-enhancing agents, as they can improve host defense against pathogens and modulate adaptive immunity¹⁷. Furthermore, previous studies have reported that many kinds of polysaccharides have potential and/or potent capabilities to prevent oxidative damages in living tissues due to their ability in scavenging free radicals, and they can protect normal tissues against oxidative stress^{18,19}. *Dioscorea bulbifera* has been used as a traditional Chinese medicine for thousands of years. However, it remains to be explored whether the polysaccharides of *Dioscorea bulbifera* can be used to prevent side effects of CTX chemotherapy.

The anti-cervical cancer effect of *Dioscorea bulbifera* polysaccharides in mice has been preliminarily shown in our previous study²⁰. In the current study, as a step to investigate whether the combined use of crude *Dioscorea bulbifera* polysaccharides (DBLP) and cyclophosphamide (CTX) could be useful in cervical cancer treatment, we explored the effect of *Dioscorea bulbifera* polysaccharides plus CTX combination in treating cervical cancer in tumor-bearing mice. We hypothesized that *Dioscorea bulbifera* polysaccharides could attenuate CTX treatment-induced immunosuppression and oxidation, and to improve the anti-tumor effect of CTX.

Results

Treatment effects on animal status and movement. In this study, treatment effects on appearances, behaviours and weight gains of animals were examined, which were found not significantly affected in all treatment groups except for the negative control. Animals could move about freely. Their furs looked smooth and normal, and their food intakes and water consumption appeared also normal.

Treatment effects on changes in body weights were shown in Table 1. By the end of the experiment, while the normal blank control mice had a 38.1% increase in weights, mice in the negative control group (tumor group without any treatments) had the least growth (17.7% increase, $P < 0.01$ compared to all other groups), which could be due to the tumor's influence. This was followed by the CTX alone group (positive control, 24.6% increase) which could be due to the toxicity of CTX that is known to damage some normal tissues including gut mucosa, bone and bone marrow²¹. However, weight gains of mice in the other groups did not show obvious differences when compared to the blank controls. The weight gains of mice with polysaccharide alone treatment markedly improved when compared to the negative control group. In the two groups treated with CTX plus polysaccharides, the weight gains were almost the same as that of the blank control group, which could be due to the enhanced antitumor effect and reduced toxicity of CTX to normal tissues when it was used in combination with polysaccharides. These findings suggest that the nutritional state and general wellbeing of the animals were the best in the combination treatment group and were the worst in the negative control group.

Treatment effects on tumor growth. Effects of CTX treatment with or without low or high dose of DBLP on the tumor inhibition rate were analyzed 15 days after tumor cell inoculation (Table 2). When there was no drug treatment (negative control group), the tumor was grown to around 3.3 g. CTX alone treatment (positive control group) significantly suppressed tumor growth (65.26% inhibition; $P < 0.01$ vs negative control). Compared to the negative control, DBLP alone treatment also inhibited tumor growth (25.68% inhibition for low dose and 37.46% for high dose, both at $P < 0.01$). Compared with the CTX alone group, the tumor inhibition rates of the combination groups showed trends of being higher despite the lack of statistically significant differences, being 5.74% higher in CTX + low dose group and 9.06% higher in CTX + high dose group than that in CTX alone group. These indicate that the effect of DBLP plus CTX is slightly better than CTX treatment alone in suppressing tumor growth, suggesting that effect of CTX in tumor inhibition may be potentially enhanced by DBLP.

Treatment effects on thymus and spleen gland/body weight indices. To examine potential immunomodulatory effects of CTX treatment with or without DBLP, the thymus and spleen/body weight indexes of

Group	Tumor weight (g)	Inhibition rate (%)
Positive control	1.15 ± 0.50	65.26 ± 0.02**
Negative control	3.31 ± 0.49	0
Low dose group	2.46 ± 0.17	25.68 ± 0.65**
High dose group	2.07 ± 0.45	37.46 ± 0.08**
Low dose group + CTX	0.96 ± 0.18	71.00 ± 0.63**
High dose group + CTX	0.85 ± 0.19	74.32 ± 0.61**

Table 2. Effects of CTX treatment with or without DBLP on U14 solid tumor growth in mice. Compared with the negative control group, **P < 0.01. CTX – cyclophosphamide.




Figure 1. Effects of CTX treatment with or without DBLP on thymus and spleen gland/body weight indices in tumor-bearing mice. Blank, blank control; Negative, negative control; Positive, positive control; Low, low dose DBLP group; High, high dose DBLP group; Low + CTX, low dose DBLP group + CTX; High + CTX, high dose DBLP group + CTX. Data were expressed as mean ± SD of 10 mice. *P < 0.05 and **P < 0.01 compared to negative control, #P < 0.05 and ##P < 0.01 compared to positive control.

treated animals were analyzed (Fig. 1). It can be seen that, when compared with the no-tumor blank control group, the thymus index in negative control group (tumor-bearing without drug treatment) was lower (P < 0.01) and the spleen gland index showed trends of being lower despite a lack of statistically significant differences. This suggests that tumor causes a decline in the immunity of the mice. Compared with the negative control group, the thymus index and spleen gland index were lower in positive control group (P < 0.01) and higher in the DBLP alone groups (P < 0.01). These findings indicated that immunosuppression could be caused by CTX and that DBLP had an immunomodulatory effect. The thymus index in the combination groups were higher than that in the positive control group (P < 0.01), and the spleen gland index in the CTX plus high dose DBLP combination group was higher than that in the positive control group (P < 0.05). These results indicate that DBLP may potentially overcome the immunosuppressive action of CTX to a certain extent.

Treatment effects on contents of CD⁴⁺ and CD⁸⁺ T-cells in peripheral blood. The immunomodulatory effects of CTX treatment with or without DBLP were further examined on the cellular level. Peripheral blood CD⁴⁺ and CD⁸⁺ T-cell contents were analysed by flow cytometry (Fig. 2) and data are presented in Table 3. Compared with the blank control group, the CD⁴⁺/CD⁸⁺ value in negative control group was unchanged, suggesting that tumor bearing did not affect ratio of T-cell subpopulations. The CD⁴⁺/CD⁸⁺ value after CTX alone treatment (positive control group) had an increased trend when compared with the negative control group, as its CD⁴⁺ gated % was increased from 70.80 to 83.26 and CD⁸⁺ gated % decreased from 3.95 to 1.85 (Fig. 2 and Table 3). After DBLP alone treatment (DBLP group), the CD⁴⁺/CD⁸⁺ value was lower than the negative control group, with its CD⁴⁺ gated % being decreased from 70.80 to 67.45 and CD⁸⁺ gated % increased from 3.95 to 4.98. After the combination treatment, the CD⁴⁺/CD⁸⁺ value tended to be higher than that in the negative control group and was lower than that in the positive control group.

Treatment effects on serum and tissue total superoxide dismutase (T-SOD) activities. To examine potential oxidative stress-modulatory effects of CTX treatment with or without DBLP following tumor cell inoculation, activity levels of the total superoxide dismutase (T-SOD, an antioxidant enzyme) in the serum (Fig. 3A) and in the thymus, spleen gland, liver and kidney (Fig. 3B) were analyzed in treated animals. Tumor growth alone (negative control group) decreased the T-SOD activity when compared with the blank control group (P < 0.01) (Fig. 3A). Following CTX (positive control) or DBLP treatment, the serum T-SOD level was increased when compared with the negative control group (P < 0.01). The T-SOD activity in the CTX and high dose DBLP combination treatment group was higher than that in the CTX alone positive control group (P < 0.01).




Figure 2. Representative graphs of flow cytometry analyses on effects of CTX treatment with or without DBLP on CD⁴⁺ and CD⁸⁺ T-cell contents in peripheral blood of tumor-bearing mice ((A) blank control; (B) positive control; (C) negative control; (D) high dose DBLP; (E) high dose DBLP + CTX).

Group	CD ⁴⁺ gated %	CD ⁸⁺ gated %	CD ⁴⁺ /CD ⁸⁺
Blank control	66.22	3.85	17.2
Negative control	70.80	3.95	17.92
Positive control	83.26	1.85	45.01
high dose DBLP	67.45	4.98	13.54
high dose DBLP + CTX	67.18	3.04	22.10

Table 3. Effects of CTX treatment with or without DBLP on the percentages of peripheral blood T-lymphocyte subpopulations in tumor-bearing mice. CTX – cyclophosphamide; DBLP – *Dioscorea bulbifera* polysaccharides.

As shown in Fig. 3B, tumor growth alone (negative control group) decreased the T-SOD activities in all tissues examined when compared with the blank control group ($P < 0.01$). Following CTX (positive control) treatment, the T-SOD activity was lower than that in the negative control group ($P < 0.01$). Compared with the positive control group, the T-SOD activity increased in the combination treatment groups ($P < 0.01$). These data demonstrated that SOD activity in serum or in various tissues could be reduced by the tumor growth in mice, and that it can be further reduced by CTX treatment in tumor-bearing mice. However, this reduction could be slowed down by DBLP treatment and the combined use of DBLP and CTX can increase the T-SOD levels when compared to CTX-alone treatment in tumor-bearing mice.

Treatment effects on serum LDH activity and MDA content. To further examine modulatory effects of treatment with CTX with or without DBLP on tissue damage and oxidative stress, serum activity of lactic acid dehydrogenase (LDH, a marker of normal tissue damage) and contents of malondialdehyde (MDA, a lipid peroxidation product) were analyzed in treated animals (Fig. 4). Tumor cell inoculation and tumor growth (negative control group) significantly increased the serum LDH activity (Fig. 4A) and MDA content (Fig. 4B) when




Figure 3. Effects of CTX treatment with or without DBLP on serum (A) and tissue (B) total superoxide dismutase (T-SOD) activities in tumor-bearing mice. Blank, blank control; Negative, negative control; Positive, positive control; Low, low dose DBLP group; High, high dose DBLP group; Low + CTX, low dose DBLP group + CTX; High + CTX, high dose DBLP group + CTX. Data were expressed as mean \pm SD of 10 mice. ** $P < 0.01$ compared to negative control, and ### $P < 0.01$ compared to positive control.

compared with the blank control group (16.1 folds for LDH and 2.3 folds for MDA, $P < 0.01$). LDH activity of CTX treatment alone (positive control) and DBLP alone treatment all decreased when compared with the negative control group ($P < 0.01$). Similarly, CTX treatment alone (positive control) and DBLP alone treatment also reduced serum MDA content when compared with the negative control group ($P < 0.01$). The LDH activities in the combination treatment groups were lower than that in the positive control group ($P < 0.01$). Similarly, the serum MDA contents in the combination treated groups were lower than that in the positive control group ($P < 0.01$).

Discussion

Cyclophosphamide (CTX) is a commonly used drug for cancer chemotherapy (eg for cervical cancer) and its high doses are known to cause severe lymphopenia and immunosuppression and oxidative stress to normal tissues in cancer patients. In our recent study, we observed an anti-cervical cancer property of *Dioscorea bulbifera* polysaccharides (DBLP) in mice²⁰. In the current study, we explored the treatment benefit effects of adjuvant treatment with DBLP in tumor-bearing mice. We observed that combined use of DBLP and CTX showed a better anti-tumor effect, and that tumor and/or CTX-induced immunosuppression and oxidative stress could be ameliorated by DBLP in tumor-bearing mice.

Previously, polysaccharides isolated from *Alchornea cordifolia* had been found to possess an anti-tumor effect¹⁵. Similarly, in our recent study, DBLP has been shown to have an anti-tumor property in mice bearing U14 cervical carcinoma²⁰. In the current study, we observed that DBLP treatment alone also inhibited growth of U14 cervical tumor dose-dependently (25.6% inhibition for low dose and 37.6% for high dose). In addition, DBLP and CTX combination treatment showed a trend of having a higher ability in inhibiting tumor growth than CTX treatment alone, suggesting that the effect of CTX in inhibiting tumor could potentially be strengthened by DBLP supplementation.

Our data demonstrated that U14 solid tumor growth in mice causes a decline in the immunity as shown particularly by a significantly lower thymus index, and that CTX treatment can further cause immunosuppression (lower thymus index and spleen gland index). The thymus is an important immune organ, being the central hematopoietic site for making T cells, which are major players of the adaptive immune system in vertebrates²². The spleen is the largest secondary immune organ in the body, and it plays an important role in maintaining immune homeostasis^{23,24}. Suggesting its positive immunomodulatory effect, our data showed that DBLP can attenuate the immunosuppressive effect caused by tumor growth or by the combination of tumor growth and CTX chemotherapy. Chen *et al.*²⁵ and Wang *et al.*²⁶ obtained a similar tendency of changes in thymus index and




Figure 4. Effects of CTX treatment with or without DBLP on serum lactic acid dehydrogenase (LDH) activity (A) and malondialdehyde (MDA) content (B) in tumor-bearing mice. Blank, blank control; Negative, negative control; Positive, positive control; Low, low dose DBLP group; High, high dose DBLP group; Low + CTX, low dose DBLP group + CTX; High + CTX, high dose DBLP group + CTX. Data were expressed as mean \pm SD of 10 mice. **P < 0.01 compared to negative control, and ##P < 0.01 compared to positive control.

spleen gland index as in our study when they respectively studied polysaccharides from *Polygoni Multiflori Radix* Praeparata and *Strongylocentrotus nudus* eggs.

The current study has also examined treatment effects on peripheral blood T-cell subpopulation ratio. Interestingly, while tumor bearing alone was shown not to affect CD^{4+}/CD^{8+} value, CTX treatment significantly increased the CD^{4+}/CD^{8+} value in the tumor-bearing mice. Furthermore, DBLP treatment was found to lower the CD^{4+}/CD^{8+} value in the tumor-bearing mice, and DBLP+CTX combination treatment significantly attenuated CTX effect in lifting the CD^{4+}/CD^{8+} value. While the CD^{4+}/CD^{8+} value as a estimation of overall immunity status is still being debated (with some literatures suggesting lower CD^{4+}/CD^{8+} values representing better immunity²⁷, and other literatures suggesting the contrary²⁸), our results indicated that a lower CD^{4+}/CD^{8+} value may represent a better overall immunity status in this tumor bearing and CTX chemotherapy setting. Our results suggest that immunosuppression can be caused by CTX chemotherapy, which can be attenuated to a certain extent by DBLP supplementary treatment in tumor-bearing mice.

Increased oxidative stress, representing an imbalance between intracellular production of free radicals and the cellular defence mechanisms²⁹, has long been recognized to play an important role in cancers and in cancer treatment-induced adverse effects³⁰. To confirm the anti-oxidative damage action mechanism of DBLP in inhibiting tumor growth and countering CTX chemotherapy-induced adverse effects, the current study has investigated effects of U14 solid tumor growth and CTX chemotherapy with/without DBLP treatment on levels of 3 molecules related to oxidative stress, namely superoxide dismutase (SOD), lactic acid dehydrogenase (LDH), and malondialdehyde (MDA). SOD is an enzyme that plays an important role in maintaining the balance of oxidation and antioxidation and thus protecting cells from oxidative stress by removing superoxide anion free radical ($O_2^{\cdot-}$) of aerobic metabolism. LDH is normally an important enzyme of energy metabolism in the body, and an increase of LDH content has been predominantly seen in malignant disease which can lead to serious damage to normal cells³¹, and recently it has been found that its inhibition induces oxidative stress and suppresses tumor progression³². Malondialdehyde (MDA) is one secondary product of lipid peroxidation and has been extensively studied as a potential biomarker for oxidative stress³³. Here, our analyses showed that U14 solid tumor growth can significantly induce oxidative stress in mice as it causes a reduction of SOD activity in serum and various tissues but increases in serum LDH activity and MDA content. CTX chemotherapy further intensifies oxidative stress in tumor-bearing mice as it further reduces serum/tissue SOD activity (which is consistent with a previous report that CTX can decrease activity of SOD of liver³⁴), increases serum LDH activity (which has been associated with more serious toxicity of CTX³⁵), and elevates serum MDA contents (which is consistent with a previous finding of increased levels of MDA following CTX treatment³²).

Group	1	2	3	4	5	6	7
Distilled water (ml) ^a	0.2	0.2					
Low dose DBLP (100 mg/kg) (ml) ^a				0.2		0.2	
High dose DBLP (150 mg/kg) (ml) ^a					0.2		0.2
CTX (ml) ^b			0.2			0.2	0.2

Table 4. Experiment grouping and treatments received. ^aIntragastric gavage. ^bIntraperitoneal injection; CTX – cyclophosphamide; DBLP – *Dioscorea bulbifera* polysaccharides.

However, in tumor-bearing mice, the reduction of SOD levels was shown to be slowed down by DBLP treatment, and the combined use of DBLP and CTX increased the SOD levels when compared to CTX-alone treatment. Consistent with our findings, Chen *et al.*²⁵ obtained a similar tendency of changes in SOD activity in the serum of mice treated with a polysaccharide from *Polygoni Multiflori Radix Praeparata*. Similarly, Yu Q. *et al.* observed the same tendency of treatment effects of *Ganoderma atrum* polysaccharide on liver and kidney SOD levels in mice³⁶. Furthermore, the current study observed that the serum LDH activity and serum MDA content in tumor-bearing mice can be decreased by DBLP treatment alone, and that CTX and DBLP combination treatment (particularly with the high dose DBLP) can reduce tumor-induced LDH activity and MDA content to a greater extent than the treatment with CTX alone. Previously, Liu *et al.*³⁷ found that serum LDH activity in mice could be decreased by treatment with the polysaccharides extracted from *Zizyphus jujube* cv. Huanghetanzao, and this finding was partly consistent with our data on DBLP effects on serum LDH activity. Similarly, it was previously demonstrated that CTX-induced increased MDA content in mice could be relieved by treatments with polysaccharides derived from *Polygoni Multiflori Radix Praeparata* and polysaccharides from *G. lucidum*^{25,38}, and here our results show a similar tendency of treatment effects on serum MDA contents with treatment with DBLP. Taken together, data of the current study suggest that lipid oxidation of serum and tissues in tumor-bearing mice can be induced by tumor growth itself and by CTX chemotherapy, and that this oxidative stress can be attenuated by DBLP treatment. Furthermore, combined use of DBLP and CTX can attenuate serum and tissue oxidation induced by CTX treatment.

While various previous studies have demonstrated biological activities of polysaccharides, findings from the current study also suggest that polysaccharides extracted were active ingredients responsible for the anti-tumor effect seen in our study. In this study, amounts of extract given to the animals (per body weights) and the anti-tumor effects observed were all based on the amounts of polysaccharides given. In addition, in the current study, polysaccharides were extracted from *Dioscorea bulbifera* of 4 different batches, and the resulting polysaccharide extracts all consistently showed an anti-tumor activity. Consistency of the anti-tumor effect of different batches of polysaccharides extracted was also reported recently²⁰.

In conclusion, the combined use of DBLP and CTX displays a better anti-tumor effect than DBLP or CTX treatment alone in tumor-bearing mice. DBLP treatment can increase thymus and spleen gland indices, and DBLP and CTX combination treatment can improve the CD⁴⁺/CD⁸⁺ T-cell ratio when compared to CTX treatment alone. Furthermore, compared to CTX treatment alone, the combination treatment can increase the SOD activity in serum and tissues and reduce serum LDH activity and MDA content. This study suggests that combination use of DBLP with CTX can enhance the anti-tumor effect of CTX and can ameliorate the immunosuppression and lipid oxidation side effects caused by CTX in tumor-bearing mice.

Materials and Methods

Reagents. *Dioscorea bulbifera* L. was purchased from Tangren Drugstore of Qinhuangdao in China. Crude polysaccharides of *Dioscorea bulbifera* L. (DBLP) were extracted as described previously²⁰, and were composed of mannose (Man 1.8%), galactose (Gal 18.4%), xylose (Xyl 1.2%), arabinose (Ara 0.7%), glucose (Glu 40.7%), galacturonic acid (GalA 35.8%), and glucuronic acid (GluA 1.4%). Cyclophosphamide (CTX) was obtained from Shanxi Powerdone Pharmaceuticals Co (Lot number 1008421; Shanxi, China) and diluted to 25 mg/ml in distilled water before use. Mouse cervical cancer U14 cells were purchased from Tumor Cell Bank of Chinese Academy of Medical Sciences (Beijing, China). Female Kunming mice of about 18 g were purchased from Experimental Animal Center of Chinese Academy of Military Medical Sciences (Beijing, China). Lactic acid dehydrogenase (LDH) kit, total superoxide dismutase (T-SOD) kit, and malondialdehyde (MDA) kit were all purchased from Nanjing Jiangcheng Science and Technology Co (Nanjing, China). Anti-mouse CD⁴⁺ and anti-mouse CD⁸⁺ monoclonal antibodies were obtained from Pharmingen (San Diego, CA). All other chemicals used were of analytical grade.

Animal model and treatments. Adult female Kun Ming specific pathogen free mice (6 weeks old, about 18 g) were divided into seven groups randomly, which were blank control, no drug treatment negative control, CTX alone positive control, low dose DBLP alone, high dose DBLP alone, low dose DBLP+CTX, and high dose DBLP+CTX, respectively (Table 4) (n = 10/group). The blank control group mice (group 1) were not inoculated with tumor cells, while the other six groups (groups 2–7) received subcutaneous injection with U14 tumor cells (0.2 mL of 2×10^7 cells/mouse, to the outer of the right fore limb). This was taken as day 0 and the experimental treatment started 24 h later, with groups receiving water or DBLP gavage or CTX intraperitoneal injection (0.2 mL, 25 mg/kg body weight) (Table 4). This work was approved by the institutional animal ethics committee (Yanshan University, Hebei, China), and the methods were carried out in accordance with the approved guidelines.

The status and body weights of mice. Food intake, water consumption, furs, and movement of mice were monitored during the experiments. Body weights were measured initially and 24 hours after the last DBLP dose (or fifteen days following tumor cell inoculation).

Tumor, thymus, and spleen sizes. Fifteen days later and 24 hours after the last dose, all the mice were humanely killed. Tumor block, thymus and spleen glands were dissected and weighed, and then tumor inhibition rate (%), thymus index and spleen gland index were calculated. The tumor inhibition rate (%) was calculated as [(Average tumor weight of control group – Average tumor weight of drug group)/Average tumor weight of control group] × 100. The thymus or spleen gland index was calculated as (Thymus or spleen gland weight/Body weight without tumor) × 10.

CD⁴⁺ and CD⁸⁺ T-cell contents. By the end of the experiment on the 16th day, peripheral blood of all groups was collected for examination of treatment effects on CD⁴⁺ and CD⁸⁺ T-cell contents immediately after the mice were killed. Peripheral blood mononuclear cells were isolated by centrifugation and were stained with FITC-conjugated anti-mouse CD⁴⁺ and PE-conjugated anti-mouse CD⁸⁺ antibodies. Cells were analyzed in an Epics-XLII flow cytometer, gated properly and a total of 10000 events were acquired and analyzed using Expo 32 ADC Analysis Software.

Oxidative stress. For examining treatment effects on oxidative stress, by the end of the experiment on the 16th day, sera were obtained from peripheral blood samples. The total superoxide dismutase (T-SOD) activity in serum was detected using the T-SOD kit as instructed. In addition, liver, kidney, thymus, and spleen gland were collected and homogenized for measuring the SOD activity, lactic acid dehydrogenase (LDH) activity and malondialdehyde (MDA) content. LDH activity and MDA content were determined using LDH and MDA kits respectively as instructed.

Statistics. All data were expressed as the means ± SD. An one-way ANOVA using SPSS 13.0 software was used to conduct a statistical comparison of differences among the groups and a value of $P < 0.05$ was considered as statistically significant.

References

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics. *CA Cancer J. Clin.* **62**, 10–29 (2012).
2. Jemal, A. *et al.* Global cancer statistics. *CA Cancer J. Clin.* **61**, 69–90 (2011).
3. Wang, Y. X., Yu, H., Zhang, Y. Y., Liu, Y. Q., Ge, X. & Wu, X. K. Emodin induces apoptosis of human cervical cancer hela cells via intrinsic mitochondrial and extrinsic death receptor pathway. *Cancer Cell Int.* **16**, 70 (2013).
4. Ehrke, M. J. Immunomodulation in cancer therapeutics. *Int. Immunopharmacol.* **3**, 1105–1119 (2003).
5. Boyd, V. L., Robbins, J. D., Egan, W. & Ludeman, S. M. 31P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites. *J. Med. Chem.* **29**, 1206–10 (1986).
6. Huitema, A. D., Smits, K. D., Mathôt, R. A., Schellens, J. H., Rodenhuis, S. & Beijnen, J. H. The clinical pharmacology of alkylating agents in high-dose chemotherapy. *Anticancer Drugs* **11**, 515–33 (2000).
7. Sladek, N. E. Metabolism of oxazaphosphorines. *Pharmacol. Ther.* **37**, 301–55 (1988).
8. Ozer, H., Cowens, J. W., Colvin, M., Nussbaum-Blumenson, A. & Sheedy, D. *In vitro* effects of 4-hydroperoxy cyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration. *J. Exp. Med.* **155**, 276–290 (1982).
9. Gladstone, D. E. *et al.* High-dose cyclophosphamide for severe systemic lupus erythematosus. *Lupus* **11**, 405–410 (2002).
10. Gate, L., Paul, J., Ba, G. N., Tew, K. D. & Tapiero, H. Oxidative stress induced in pathologies: the role of antioxidants. *Biomed. Pharmacother.* **53**, 169–180 (1999).
11. Friery, O. P. *et al.* Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. *Br. J. Cancer* **82**, 1469–1473 (2000).
12. Zhong, Z. G., Zhao, S. Y., Lv, J. Y. & Li, P. Experimental study on antitumor effect of extracts from *Cestrum nocturnum* *in vivo*. *Zhong Yao Cai* **31**, 1709–12 (2008) (in Chinese).
13. Zhu, X. L., Chen, A. F. & Lin, Z. B. Ganoderma lucidum polysaccharides enhance the function of immunological effector cells and hematopoiesis of immunosuppressed mice. *J. Ethnopharmacol.* **111**, 219–226 (2007).
14. Chen, J., Hu, T. & Zheng, R. Antioxidant activities of Sophora subprostrate polysaccharide in immunosuppressed mice. *Int. Immunopharmacol.* **7**, 547–553 (2007).
15. Kouakou, K. *et al.* Immunomodulatory activity of polysaccharides isolated from *Alchornea cordifolia*. *J. Ethnopharmacol.* **146**, 232–242.
16. Li, J. E., Nie, S. P., Xie, M. Y. & Li, C. Isolation and partial characterization of a neutral polysaccharides from *Mosla chinensis* Maxim. cv. Jiangxiangru and its antioxidant and immunomodulatory activities. *J. Funct. Foods* **6**, 410–418 (2014).
17. Li, J. *et al.* Enhancement of astragalus polysaccharide on the immune responses in pigs inoculated with foot-and-mouth disease virus vaccine. *Int. J. Biol. Macromol.* **49**, 362–368 (2011).
18. Liu, F., Ooi, V. & Chang, S. Free radical scavenging activities of Mushroom polysaccharide extracts. *Life Sci.* **60**, 763–771 (1997).
19. Peterszegi, G., Robert, A. & Robert, L. Protection by L-fucose and fucose-rich polysaccharides against ROS-produced cell death in presence of ascorbate. *Biomed. Pharmacother.* **57**, 130–133 (2003).
20. Cui, H. X. Antitumor activity and possible mechanism of crude polysaccharides from *Discorea bulbifera* L. on the mice bearing U14 cervical carcinoma. *AMR.* **560–561**, 374–379 (2012).
21. Xian, C. J., Cool, J., Gangelen, J. V., Foster, B. & Howarth, G. Effects of etoposide and cyclophosphamide acute chemotherapy on growth plate and metaphyseal bone in rats. *Cancer Biology & Therapy* **6**, 170–77 (2007).
22. Gordon, J. & Manley, N. R. Mechanisms of thymus organogenesis and morphogenesis. *Development* **138**, 3865–3878 (2011).
23. Mebius, R. E. & Kraal, G. Structure and function of the spleen. *Nat. Rev. Immunol.* **5**, 606–616 (2005).
24. Cesta, M. F. Normal structure, function and histology of the spleen. *Toxicol. Pathol.* **34**, 455–465 (2006).
25. Chen, Q., Zhang, S. Z. & Ying, H. Z. Chemical characterization and immunostimulatory effect of a polysaccharide from *Polygoni Multiflori Radix Praeparata* in cyclophosphamide-induced anemic mice. *Carbohydr. Polym.* **88**, 1476–1482 (2012).
26. Wang, H., Wang, M. Y. & Chen, J. A polysaccharide from *Strongylocentrotus nudus* eggs protects against myelosuppression and immunosuppression in cyclophosphamide-treated mice. *Int. Immunopharmacol.* **11**, 1946–1953 (2011).
27. Huyan, X. H., Lin, Y. P., Gao, T., Chen, R. Y. & Fan, Y. M. Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice. *Int. Immunopharmacol.* **11**, 1293–1297 (2011).

28. Hald, S. M. *et al.* CD4/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy. *Lung Cancer* **80**, 209–215 (2013).
29. Kucukkurt, I., Ince, S., Aytekin, I. & Birdane, Y. O. The effects of flumethrin and flumethrin + vitamin C application on oxidative stress biomarkers in Chios sheep. *Kocatepe Vet. J.* **3**, 13–17 (2010).
30. Zhan, Z. J., Zhou, Z. G. & Shan, W. G. Preparation and characterization of Cu,Zn-superoxide dismutase covalently modified by polyunsaturated fatty acids. *Biochemistry (Moscow)* **74**, 1266–1269 (2009).
31. Kovesi, T. A. & Hsu, E. Changes in lactate dehydrogenase isoenzymes associated with relapse of childhood acute lymphocytic leukemia. *Pediatr. Hematol. Oncol.* **11**, 527–33 (1994).
32. Le, A. *et al.* Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. *Proc. Nat. Acad. Sci. USA* **107**, 2037–42 (2010).
33. Nielsen, F., Mikkelsen, B. B., Nielsen, J. B., Andersen, H. R. & Grandjean, P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. *Clin Chem.* **43**, 1209–14 (1997).
34. Premkumar, K. *et al.* Effect of Spirulina fusiformis on cyclophosphamide and mitomycin-C induced genotoxicity and oxidative stress in mice. *Fitoterapia* **72**, 906–911 (2001).
35. Ying, Y. *et al.* The influence of cyclophosphamide on the growth, peripheral blood biochemistry index and organ coefficient of SD rat. *Chin. Anim. Husb. Vet. Med.* **37**, 18–21 (2010).
36. Yu, Q., Nie, S. P. & Wang, J. Q. Chemoprotective effects of Ganoderma atrum polysaccharide in cyclophosphamide-induced mice. *Int. J. Biol. Macromol.* **64**, 395–401 (2014).
37. Liu, G. P., Liu, X. Q. & Zhang, Y. C. Hepatoprotective effects of polysaccharides extract from Zizyphus jujube cv. Huanghetanzao. *Int. J. Biol. Macromol.* **76**, 169–175 (2015).
38. Li, X. L., Zhou, A. G. & Li, X. M. Inhibition of Lycium barbarum polysaccharides and Ganoderma lucidum polysaccharides against oxidative injury induced by Y-irradiation in rat liver mitochondria. *Carbohydr. Polym.* **69**, 172–178 (2007).

Acknowledgements

H.C., T.L. and Y.S. are supported by Hebei Province Natural Science Foundation of China (D2014203102), and Young Scientists Fund in Colleges and Universities in Hebei Province Science and Technology Research Project. L.W. is supported by Australian National Health and Medical Research Council (NHMRC) Postgraduate Research Scholarship, and C.J.X. is supported by NHMRC Senior Research Fellowship.

Author Contributions

Study design: H.C. and T.L. Study conduct: C.J.X. Data collection: H.C., T.L. and Y.S.. Data analysis: H.C., T.L., L.W. and Y.S. Data interpretation: H.C. and T.L. Drafting manuscript: H.C., L.W. and C.J.X. Revising manuscript content: H.C. and C.J.X. All authors have read and approved the final submitted manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Cui, H. *et al.* Dioscorea bulbifera polysaccharide and cyclophosphamide combination enhances anti-cervical cancer effect and attenuates immunosuppression and oxidative stress in mice. *Sci. Rep.* **6**, 19185; doi: 10.1038/srep19185 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>